What's new? The USPSTF has revised the recommended ages and pack-years for lung cancer screening. It expanded the age range to 50 to 80 years (previously 55 to 80 years), and reduced the pack-year history to 20 pack-years of smoking (previously 30 pack-years). How to implement this recommendation?

The USPSTF recommends yearly lung cancer screening with low-dose computed tomography (LDCT) for people who have a history of heavy smoking, and smoke now or have quit within the past 15 years, and are between 50 and 80 years old.

The National Lung Screening Trial (NLST) is a randomized multicenter study comparing low-dose helical computed tomography (CT) with chest radiography in the screening of older current and former heavy smokers for early detection of lung cancer, which is the leading cause of cancer-related death in the United States.

The 10-pillar model reflects the elements required to support a successful LCS program: eligibility, education, examination order- ing, image acquisition, image review, communication, referral net- work, quality improvement, reimbursement, and research frontiers.

For the 2023 update (Version 1.2023), the NCCN panel expanded the criteria to include patients with stage IIIB (only T3N2) disease, as previously described. Osimertinib is recommended in these settings for EGFR exon 19 deletions or EGFR exon 21 L858R mutations, which are the most common EGFR mutations.

The only recommended screening test for lung cancer is low-dose computed tomography (also called a low-dose CT scan, or LDCT). During an LDCT scan, you lie on a table and an X-ray machine uses a low dose (amount) of radiation to make detailed images of your lungs.

USPSTF Guidelines 2021 For screening to be most effective, more of the high-risk population should be screened annually - currently screening rates remain low among those at high risk. Nationally, only 5.8% of those at high risk were screened.

Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lung cancers. Chest computed tomography imaging is the optimal imaging modality for surveillance.

CPT 71271: CT, thorax, low dose for cancer screening without contrast material. This code became effective January 1, 2021.

Advanced technology: UCLA Health lung specialists use low-dose computed tomography (LDCT) scanning, the gold standard for early detection of lung cancer. LDCT creates detailed images of the lungs with significantly less radiation than a chest X-ray.

About The Event The 2023 Great Debates and Updates in Lung Cancers is a multi-day, debate-driven conference focusing on the treatment of thoracic oncology. A comprehensive overview of the most significant advances in the treatment of lung cancer, as well as valuable take-home information, will be discussed.

Between August 1, 2022, and July 31, 2023, the FDA approved 14 new cancer therapies and expanded the approved use of 12 therapies to encompass new cancers. The therapies include a range of cell-signaling inhibitors, antibody-drug conjugates, bispecific antibodies, and immune checkpoint inhibitors.